^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CAR.70/IL15-transduced CB-NK cells

i
Other names: CAR.70/IL15-transduced CB-NK cells, CAR.70-engineered IL15-transduced cord blood-derived NK cells
Associations
Company:
UT MD Anderson Cancer Center
Drug class:
NK cell stimulant
Related drugs:
Associations
over1year
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
P1/2, N=94, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2023 --> Aug 2026 | Trial primary completion date: Aug 2023 --> Aug 2026
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
over1year
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
almost2years
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells